Inhalable RNA Therapeutics Market
完整報告名稱與涵蓋範圍
Inhalable RNA Therapeutics Market Size, Share & Trends Analysis Report, By RNA Modality (Inhaled mRNA and Self-Amplifying RNA, Inhaled siRNA and Antisense Oligonucleotides, Inhaled Gene Editing and Other RNA Modalities), By Delivery Platform (Lipid Nanoparticles Optimized for Aerosolization, Polymer and Peptide Carriers, Naked and Conjugated Oligonucleotides), By Indication (Cystic Fibrosis and Primary Ciliary Dyskinesia, Asthma, COPD and Fibrotic Lung Disease, Respiratory Infections and Vaccines, Lung Cancer), By Development Stage, By Region, and Segment Forecasts, 2026-2035
報告摘要
The inhalable RNA therapeutics market covers messenger RNA, self-amplifying RNA, siRNA, antisense and gene-editing medicines delivered to the lung by aerosol, along with the aerosol-compatible nanoparticle and carrier platforms and nebulizer technologies developed for them. Inhaled biologics that are not RNA-based are covered in a separate InsightAce study, and injectable RNA therapeutics are excluded. No inhaled RNA therapeutic is approved as of 2026, so forecast revenue is derived from clinical-stage program timelines, with near-term value residing in platform licensing and clinical supply.
The lung is an attractive target because inhalation delivers RNA directly to airway epithelium for diseases such as cystic fibrosis and primary ciliary dyskinesia, where the underlying defect is genetic and where a large minority of patients are not eligible for small-molecule modulators. Programs have shown that lipid nanoparticles can survive nebulization when formulation and mesh technology are matched, and antisense and siRNA candidates have reached mid-stage trials in cystic fibrosis and asthma. Repeat dosing tolerability, mucus penetration, aerosol stability and manufacturing of inhalation-grade nanoparticles are the key development challenges that determine which platforms advance.
Development is concentrated in the United States and Germany, with disease foundations and pharmaceutical partners funding programs. Competition involves RNA delivery specialists, oligonucleotide companies extending into inhaled routes and aerosol device makers supplying optimised nebulizers.
The InsightAce study supplies US$ forecasts for all RNA modality, delivery platform, indication and development stage and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Inhalable RNA Therapeutics Market Snapshot
Chapter 4. Global Inhalable RNA Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By RNA Modality Estimates & Trend Analysis
5.1. RNA Modality & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by RNA Modality:
5.2.1. Inhaled mRNA and Self-Amplifying RNA
5.2.2. Inhaled siRNA and Antisense Oligonucleotides
5.2.3. Inhaled Gene Editing and Other RNA Modalities
Chapter 6. Market Segmentation 2: By Delivery Platform Estimates & Trend Analysis
6.1. Delivery Platform & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Delivery Platform:
6.2.1. Lipid Nanoparticles Optimized for Aerosolization
6.2.2. Polymer and Peptide Carriers
6.2.3. Naked and Conjugated Oligonucleotides
Chapter 7. Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. Indication & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
7.2.1. Cystic Fibrosis and Primary Ciliary Dyskinesia
7.2.2. Asthma, COPD and Fibrotic Lung Disease
7.2.3. Respiratory Infections and Vaccines
7.2.4. Lung Cancer
Chapter 8. Market Segmentation 4: By Development Stage Estimates & Trend Analysis
8.1. Development Stage & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
8.2.1. Preclinical
8.2.2. Phase 1 and Phase 2
8.2.3. Late-Stage and Commercial
Chapter 9. Inhalable RNA Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. ReCode Therapeutics, Inc.
11.2. Ethris GmbH
11.3. Arcturus Therapeutics Holdings Inc.
11.4. Translate Bio (Sanofi)
11.5. Aerami Therapeutics
11.6. Arrowhead Pharmaceuticals, Inc.
11.7. Vertex Pharmaceuticals Incorporated
11.8. Moderna, Inc.
11.9. 4D Molecular Therapeutics, Inc.
11.10. Krystal Biotech, Inc.
11.11. Cystic Fibrosis Foundation (Therapeutics Lab Partnerships)
11.12. Aptar Pharma
11.13. Aerogen Ltd.
11.14. Genevant Sciences
11.15. Boehringer Ingelheim International GmbH
圖表清單 List of Tables & Figures
Table 1. Global Inhalable RNA Therapeutics Market Revenue Forecast by RNA Modality, 2026-2035 (US$ Mn)
Figure 1. Global Inhalable RNA Therapeutics Market Segmentation and Scope Overview
Table 2. Global Inhalable RNA Therapeutics Market Revenue Forecast by Delivery Platform, 2026-2035 (US$ Mn)
Figure 2. Global Inhalable RNA Therapeutics Market Share by RNA Modality, 2026 & 2035
Table 3. Global Inhalable RNA Therapeutics Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 3. Inhaled RNA Pipeline by Modality, Delivery Platform and Phase, 2026
Table 4. Global Inhalable RNA Therapeutics Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 4. Aerosolization Compatibility of Nanoparticle Platforms and Nebulizer Technologies
Table 5. Global Inhalable RNA Therapeutics Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Inhalable RNA Therapeutics Growth Opportunity Analysis
Table 6. North America Inhalable RNA Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Inhalable RNA Therapeutics Market Participants
Table 7. Europe Inhalable RNA Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Inhalable RNA Therapeutics Market
Table 8. Asia Pacific Inhalable RNA Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Non-Modulator-Eligible Cystic Fibrosis Population as the Anchor Indication
Table 9. Strategic Developments of Leading Inhalable RNA Therapeutics Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們